Rosen Law Firm Encourages Nektar Therapeutics Investors to Secure Counsel Before Deadline

Investors who purchased Nektar securities between February 26, 2025 and December 15, 2025 may be eligible for compensation.

Mar. 23, 2026 at 5:21am

Got story updates? Submit your updates here. ›

The Rosen Law Firm, a global investor rights law firm, is reminding purchasers of Nektar Therapeutics (NASDAQ: NKTR) securities during the class period of February 26, 2025 to December 15, 2025 about the important May 5, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that Nektar made false and/or misleading statements about enrollment issues and the integrity of its REZOLVE-AA trial, which ultimately impacted investor damages.

Why it matters

This case highlights the importance of investors being aware of potential securities fraud and taking action to protect their rights. The Rosen Law Firm is encouraging affected Nektar investors to secure counsel before the lead plaintiff deadline, as a successful class action lawsuit could result in compensation for those who suffered losses.

The details

According to the lawsuit, Nektar Therapeutics is accused of making false and/or misleading statements about issues with the enrollment and protocol standards of its REZOLVE-AA trial. The lawsuit claims these issues were likely to have a significant negative impact on the trial's results, overstating the overall integrity and prospects of the trial. When the true details entered the market, investors allegedly suffered damages.

  • The class period is from February 26, 2025 to December 15, 2025, both dates inclusive.
  • The lead plaintiff deadline is May 5, 2026.

The players

Nektar Therapeutics

A biopharmaceutical company that develops innovative medicines in areas of high unmet medical need.

The Rosen Law Firm, P.A.

A global investor rights law firm that concentrates its practice in securities class actions and shareholder derivative litigation.

Got photos? Submit your photos here. ›

What they’re saying

“We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition.”

— Laurence Rosen, Founding Partner, The Rosen Law Firm

What’s next

To join the Nektar class action, investors must move the Court no later than May 5, 2026 to serve as lead plaintiff.

The takeaway

This case underscores the importance for investors to be vigilant about potential securities fraud and to seek qualified legal counsel to protect their rights and potentially recover losses. The Rosen Law Firm's track record of success in securities class actions makes them well-positioned to represent affected Nektar investors.